Revolution Medicines director plans $16.9M sale

Revolution Medicines, Inc. (RVMD) received a notice that Mark A. Goldsmith, identified as a director or officer, plans to sell 80,000 shares of common stock under Rule 144.

Rhea-AI Filing Summary

Revolution Medicines, Inc. (RVMD) received a notice that Mark A. Goldsmith, identified as a director or officer, plans to sell 80,000 shares of common stock under Rule 144. The planned sale is dated 08/21/2026, via Morgan Stanley Smith Barney LLC Executive Financial Services, and is tied to the exercise of stock options for cash. The securities information lists an aggregate market value of approximately $16,938,800.00 for these 80,000 shares, with 214,336,418 RVMD common shares outstanding. In the prior three months, Goldsmith reported selling 10,020 shares of common stock on 06/16/2026 for proceeds of $1,564,310.38.

Key Figures

Planned shares to be sold: 80,000 shares Aggregate market value of planned sale: $16,938,800.00 Shares outstanding: 214,336,418 shares +3 more

6 metrics

Planned shares to be sold 80,000 shares Common stock sale under Rule 144 planned for 08/21/2026

Aggregate market value of planned sale $16,938,800.00 Value associated with 80,000 shares of RVMD common stock

Shares outstanding 214,336,418 shares RVMD common shares outstanding referenced in the notice

Shares sold in past 3 months 10,020 shares Sale by Mark A. Goldsmith on 06/16/2026

Proceeds from prior sale $1,564,310.38 Total proceeds from 10,020 RVMD shares sold on 06/16/2026

Planned sale date 08/21/2026 Date of intended Rule 144 sale and option exercise

Key Terms

Rule 144, Exercise of Stock Options, Executive Financial Services

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Exercise of Stock Options financial

"Common | 08/21/2026 | Exercise of Stock Options | Issuer"

Executive Financial Services financial

"Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for RVMD disclose about Mark A. Goldsmith?

It discloses that Mark A. Goldsmith, a director or officer, has notified an intent to sell 80,000 shares of Revolution Medicines, Inc. common stock on 08/21/2026 under Rule 144, in connection with the exercise of stock options for cash.

How many RVMD shares does Mark A. Goldsmith plan to sell and when?

Mark A. Goldsmith plans to sell 80,000 shares of Revolution Medicines, Inc. common stock on 08/21/2026. The sale is indicated as being made pursuant to an exercise of stock options for cash.

What is the approximate market value of the RVMD shares covered by this Form 144?

The filing lists an aggregate market value of about $16,938,800.00 for the 80,000 shares of Revolution Medicines, Inc. common stock referenced in the planned Rule 144 sale.

How many Revolution Medicines (RVMD) shares are outstanding as referenced in this notice?

The Form 144 states that there are 214,336,418 shares of Revolution Medicines, Inc. common stock outstanding, as context for the planned Rule 144 sale by Mark A. Goldsmith.

What RVMD stock sales has Mark A. Goldsmith made in the last three months?

The filing reports that Mark A. Goldsmith sold 10,020 shares of Revolution Medicines, Inc. common stock on 06/16/2026, with total proceeds of $1,564,310.38, during the three months prior to the new planned sale.

Which broker is handling the planned RVMD share sale under Form 144?

The planned sale of 80,000 RVMD shares is listed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/21/2026 - 04:38 PM Accepted by SEC EDGAR 08/21/2026 - 04:37 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001246842
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Revolution Medicines, Inc.
SEC File Number	001-39219
Address of Issuer	700 Saginaw Drive Redwood City CALIFORNIA 94063
Phone	6504816801
Name of Person for Whose Account the Securities are To Be Sold	MARK A GOLDSMITH
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	80000	16938800.00	214336418	08/21/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/21/2026	Exercise of Stock Options	Issuer			80000	08/21/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
MARK A GOLDSMITH 700 Saginaw Drive Redwood City CA 94063	Common	06/16/2026	10020	1564310.38

144: Remarks and Signature

Remarks
Date of Notice	08/21/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/22/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Mark A Goldsmith
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)